Matches in SemOpenAlex for { <https://semopenalex.org/work/W2520006799> ?p ?o ?g. }
- W2520006799 endingPage "862" @default.
- W2520006799 startingPage "862" @default.
- W2520006799 abstract "Background: Allogeneic hematopoietic cell transplantation (HCT) can be curative in a subset of patients with advanced lymphoid malignancies but relapse remains a major reason for treatment failure. Donor-derived, non-specific lymphocyte infusions (DLI) can confer an immune anti-malignancy effect but can be complicated by graft-versus-host-disease (GVHD). Chimeric antigen receptor (CAR)-modified T cells directed toward CD19 have demonstrated dramatic efficacy in patients with refractory ALL and NHL. However, responses are often associated with life-threatening cytokine release syndrome. Aim: We hypothesized that infusing CAR-modified, CD19-specific T-cells after HCT as a directed DLI would be associated with a low rate of GVHD, better disease control, and a less severe cytokine release syndrome since administered in a minimal disease state. Methods: We employed a non-viral gene transfer using the Sleeping Beauty (SB) transposon/transposase system to stably express a CD19-specific CAR (designated CD19RCD28 that activates via CD3z & CD28) in donor-derived T cells for patients with advanced CD19+ lymphoid malignancies. T-cells were electroporated using a Nucleofector device to synchronously introduce two DNA plasmids coding for SB transposon (CD19RCD28) and hyperactive SB transposase (SB11). T-cells stably expressing the CAR were retrieved over 28 days of co-culture by recursive additions of g-irradiated activating and propagating cells (AaPC) in presence of soluble recombinant interleukin (IL)-2 and IL-21. The AaPC were derived from K562 cells and genetically modified to co-express CD19 as well as the co-stimulatory molecules CD86, CD137L, and a membrane-bound version of IL-15. Results: To date, we have successfully treated 21 patients with median age 36 years (range 21-62) with advanced CD19+ ALL (n=18) or NHL (n=3); 10 patients had active disease at time of HCT. Donor-derived CAR+ T cells (HLA-matched sibling n=10; 1 Ag mismatched sibling n=1; haplo family n=8; cord blood n=2) were infused at a median 64 days (range 42-91 days) following HCT to prevent disease progression. Transplant preparative regimens were myeloablative, busulfan-based (n=10) or reduced intensity, fludarabine-based (n=11). All patients were maintained on GVHD prophylaxis at time of CAR T-cell infusion with tacrolimus, plus mycophenolate mofeteil for cord, plus post-HCT cyclophosphamide for haplo donors. The starting CAR+ T-cell dose was 106 (n=7), escalated to 107 (n=6), 5x107 (n=5), and currently at 108 (n=3) modified T cells/m2 (based on recipient body surface area). Patients have not demonstrated any acute or late toxicity to CAR+ T cell infusions. Three patients developed acute grades 2-4 GVHD (liver n=1, upper GI n=1, skin=1) which was within the expected range after allogeneic HCT alone. Of note, the rate of CMV reactivation after CAR T cell infusion was 24% vs. 41 % previously reported for our patients without CAR T cell infusion (Wilhelm et al. J Oncol Parm Practice, 2014, 20:257). Nineteen patients have had at least 30 days follow-up post CAR T-cell infusion and are evaluable for disease progression. Forty-eight percent of patients (n=10) remain alive and in complete remission (CR) at median 5.2 months (range 0-21.3 months) following CAR T cell infusion. Importantly, among 8 patients who received haplo-HCT and CAR, 7 remain in remission at median 4.2 months. Conclusion: We demonstrate that infusing donor-derived CD19-specific CAR+ T cells, using the SB and AaPC platform, in the adjuvant HCT setting as pre-emptive DLI may provide an effective and safe approach for maintaining remission in patients at high risk for relapse. Graft-vs-host disease did not appear increased by administration of the donor derived CAR-T cells. Furthermore, the add-back of allogeneic T cells appears to have contributed to immune reconstitution and control of opportunistic viral infection. Disclosures Huls: Intrexon and Ziopharm: Employment, Equity Ownership. Singh:Intrexon and Ziopharm: Equity Ownership, Patents & Royalties. Olivares:Intrexon and Ziopharm: Equity Ownership, Patents & Royalties. Su:Ziopharm and Intrexon: Employment. Figliola:Intrexon and Ziopharm: Equity Ownership, Patents & Royalties. Kumar:Ziopharm and Intrexon: Equity Ownership. Jena:Ziopharm Oncology: Equity Ownership, Patents & Royalties: Potential roylaties (Patent submitted); Intrexon: Equity Ownership, Patents & Royalties: Potential royalties (Patent submitted). Ang:Intrexon and Ziopharm: Equity Ownership. Lee:Intrexon: Equity Ownership; Cyto-Sen: Equity Ownership; Ziopharm: Equity Ownership." @default.
- W2520006799 created "2016-09-23" @default.
- W2520006799 creator A5007244861 @default.
- W2520006799 creator A5008431344 @default.
- W2520006799 creator A5012044195 @default.
- W2520006799 creator A5016928938 @default.
- W2520006799 creator A5019752519 @default.
- W2520006799 creator A5024858587 @default.
- W2520006799 creator A5024875341 @default.
- W2520006799 creator A5029823622 @default.
- W2520006799 creator A5032451528 @default.
- W2520006799 creator A5032924224 @default.
- W2520006799 creator A5034104852 @default.
- W2520006799 creator A5035321251 @default.
- W2520006799 creator A5035361443 @default.
- W2520006799 creator A5046805167 @default.
- W2520006799 creator A5048913229 @default.
- W2520006799 creator A5050962913 @default.
- W2520006799 creator A5053198234 @default.
- W2520006799 creator A5053904944 @default.
- W2520006799 creator A5055885795 @default.
- W2520006799 creator A5066894053 @default.
- W2520006799 creator A5068165365 @default.
- W2520006799 creator A5069460930 @default.
- W2520006799 creator A5076557190 @default.
- W2520006799 creator A5076863688 @default.
- W2520006799 creator A5085076031 @default.
- W2520006799 creator A5090435894 @default.
- W2520006799 creator A5091083304 @default.
- W2520006799 date "2015-12-03" @default.
- W2520006799 modified "2023-09-30" @default.
- W2520006799 title "Pre-Emptive Donor Lymphocyte Infusion with CD19-Directed, CAR-Modified T Cells Infused after Allogeneic Hematopoietic Cell Transplantation for Patients with Advanced CD19+ Malignancies" @default.
- W2520006799 doi "https://doi.org/10.1182/blood.v126.23.862.862" @default.
- W2520006799 hasPublicationYear "2015" @default.
- W2520006799 type Work @default.
- W2520006799 sameAs 2520006799 @default.
- W2520006799 citedByCount "9" @default.
- W2520006799 countsByYear W25200067992016 @default.
- W2520006799 countsByYear W25200067992017 @default.
- W2520006799 countsByYear W25200067992018 @default.
- W2520006799 countsByYear W25200067992019 @default.
- W2520006799 countsByYear W25200067992021 @default.
- W2520006799 countsByYear W25200067992022 @default.
- W2520006799 crossrefType "journal-article" @default.
- W2520006799 hasAuthorship W2520006799A5007244861 @default.
- W2520006799 hasAuthorship W2520006799A5008431344 @default.
- W2520006799 hasAuthorship W2520006799A5012044195 @default.
- W2520006799 hasAuthorship W2520006799A5016928938 @default.
- W2520006799 hasAuthorship W2520006799A5019752519 @default.
- W2520006799 hasAuthorship W2520006799A5024858587 @default.
- W2520006799 hasAuthorship W2520006799A5024875341 @default.
- W2520006799 hasAuthorship W2520006799A5029823622 @default.
- W2520006799 hasAuthorship W2520006799A5032451528 @default.
- W2520006799 hasAuthorship W2520006799A5032924224 @default.
- W2520006799 hasAuthorship W2520006799A5034104852 @default.
- W2520006799 hasAuthorship W2520006799A5035321251 @default.
- W2520006799 hasAuthorship W2520006799A5035361443 @default.
- W2520006799 hasAuthorship W2520006799A5046805167 @default.
- W2520006799 hasAuthorship W2520006799A5048913229 @default.
- W2520006799 hasAuthorship W2520006799A5050962913 @default.
- W2520006799 hasAuthorship W2520006799A5053198234 @default.
- W2520006799 hasAuthorship W2520006799A5053904944 @default.
- W2520006799 hasAuthorship W2520006799A5055885795 @default.
- W2520006799 hasAuthorship W2520006799A5066894053 @default.
- W2520006799 hasAuthorship W2520006799A5068165365 @default.
- W2520006799 hasAuthorship W2520006799A5069460930 @default.
- W2520006799 hasAuthorship W2520006799A5076557190 @default.
- W2520006799 hasAuthorship W2520006799A5076863688 @default.
- W2520006799 hasAuthorship W2520006799A5085076031 @default.
- W2520006799 hasAuthorship W2520006799A5090435894 @default.
- W2520006799 hasAuthorship W2520006799A5091083304 @default.
- W2520006799 hasConcept C126322002 @default.
- W2520006799 hasConcept C203014093 @default.
- W2520006799 hasConcept C2777408962 @default.
- W2520006799 hasConcept C2777701055 @default.
- W2520006799 hasConcept C2778957590 @default.
- W2520006799 hasConcept C2779695342 @default.
- W2520006799 hasConcept C2911091166 @default.
- W2520006799 hasConcept C3875195 @default.
- W2520006799 hasConcept C502942594 @default.
- W2520006799 hasConcept C71924100 @default.
- W2520006799 hasConcept C86803240 @default.
- W2520006799 hasConcept C8891405 @default.
- W2520006799 hasConceptScore W2520006799C126322002 @default.
- W2520006799 hasConceptScore W2520006799C203014093 @default.
- W2520006799 hasConceptScore W2520006799C2777408962 @default.
- W2520006799 hasConceptScore W2520006799C2777701055 @default.
- W2520006799 hasConceptScore W2520006799C2778957590 @default.
- W2520006799 hasConceptScore W2520006799C2779695342 @default.
- W2520006799 hasConceptScore W2520006799C2911091166 @default.
- W2520006799 hasConceptScore W2520006799C3875195 @default.
- W2520006799 hasConceptScore W2520006799C502942594 @default.
- W2520006799 hasConceptScore W2520006799C71924100 @default.
- W2520006799 hasConceptScore W2520006799C86803240 @default.
- W2520006799 hasConceptScore W2520006799C8891405 @default.
- W2520006799 hasIssue "23" @default.
- W2520006799 hasLocation W25200067991 @default.
- W2520006799 hasOpenAccess W2520006799 @default.